Hellow guys, Welcome to my website, and you are watching P. Eblé - Efficacy of A/MAY/97 FMDV vaccine against heterologous challenge with a field virus [...]. and this vIdeo is uploaded by EuFMD FAST at 2019-06-14T05:47:02-07:00. We are pramote this video only for entertainment and educational perpose only. So, I hop you like our website.
| Name | P. Eblé - Efficacy of A/MAY/97 FMDV vaccine against heterologous challenge with a field virus [...] |
| Video Uploader | Video From EuFMD FAST |
| Upload Date | This Video Uploaded At 14-06-2019 12:47:02 |
| Video Discription | P. Eblé - Efficacy of A/MAY/97 FMDV vaccine against heterologous challenge with a field virus from the emerging A/ASIA/G-VII lineage in cattle Session: Improving conventional vaccines Open Session of the EuFMD – 2018 – Increasing Global Security in the supply of effective vaccines – 29-31 October 2018 -Borgo Egnazia, Italy Introduction Since 2015, outbreaks of FMD in the Middle East were increasingly caused by a new emerging viral lineage, A/ASIA/G-VII. In-vitro vaccine matching data indicated that this virus poorly matched with vaccine strains. Previous studies have shown that regardless of a poor antigenic match, high-potency vaccines can protect against heterologous challenge. We investigated whether vaccines available in our vaccine banks could protect against A/ASIA/G-VII. Because A/MAY/97 vaccine gave the best result in pilot-studies, this vaccine was tested in a potency test. Materials and methods Groups of 5 cattle were vaccinated with a full, a 1/3 and a 1/9 dose vaccine. All vaccinated and 3 control cattle were challenged intradermolingually at 21 days post vaccination with A/ ASIA/G-VII. After challenge, cattle were monitored for clinical signs and those with FMD lesions on their feet were considered non-protected. The potency of the vaccine was calculated (Spearman Kärber method). Blood samples and swabs (nose, saliva) were collected and tested for presence of virus (RT-PCR, VI). Serum was tested for antibodies to structural (VNT) and non-structural proteins (NSP-ELISA) of FMDV. Results At time of challenge, the VNT-titre of the full dose group was 2.22 (log10) against A/MAY/97, and 1.38 against A/ASIA/G-VII. All cattle from the full, 4 from the 1/3 and 2 from the 1/9 dose groups were clinically protected, resulting in a potency of 6.5 PD50/dose. No viraemia was detected in protected cattle. The amounts of virus detected in swabs of the full and 1/3 dose groups were significantly lower as compared to the controls. Discussion These data provide evidence that a high potency A/MAY/97 vaccine can protect against clinical disease when challenged with a heterologous A/ASIA/G-VII virus, even though in-vitro results predict a poor antigenic match. The extent of cross-protection is probably highly dependent on the quality and antigen load of the vaccine. More at https://eufmdlearning.works/course/view.php?id=178 |
| Category | Science & Technology |
| Tags | Science & Technology Download MP4 | Science & Technology Download MP3 | Science & Technology Download MP4 360p | Science & Technology Download MP4 480p | Science & Technology Download MP4 720p | Science & Technology Download MP4 1080p |
